The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, Denis L.; Goodman, Aaron; de Melo Gagliato, Debora; Kurzrock, Razelle

doi:10.1016/j.ccell.2020.10.001

Cited by 1,192Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Genomics and Diagnostics

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Open access

Jardim, Denis L., Goodman, Aaron, de Melo Gagliato, Debora, Kurzrock, Razelle·2021·Cancer Cell

DOI 10.1016/j.ccell.2020.10.001PMC PMC7878292

Open this paper in CoChat — free account Open PDF

Abstract

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cells. To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enabling T cell reactivation; however, response biomarkers are required, as most patients do not benefit. Higher TMB results in more neo-antigens, increasing chances for T cell recognition, and clinically correlates with better ICI outcomes. Nevertheless, TMB is an imperfect response biomarker. A composite predictor that also includes critical variables, such as MHC and T cell receptor repertoire, is needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.10.001

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In some tumour types, tumour mutational burden or neoantigen number correlates with responsiveness to immune-checkpoint inhibitors.
“In certain tumour types, the number of neoantigens in a tumour (or tumour mutational burden (TMB)) is correlated with responsiveness to ICIs67,68.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [67]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683 · see citing works
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · see citing works
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · see citing works
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · see citing works
Self-citation
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264 · see citing works
Self-citation
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · see citing works
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · see citing works
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · see citing works
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,474 · see citing works
Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Shitara, K., Özgüroğlu, M., Bang, Y., Bartolomeo, M. D., Mandalà, M., Ryu, M., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,290 · see citing works
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · see citing works
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S. C., Chaput, N., Eggermont, A. M. M., Marabelle, A., Soria, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,188 · see citing works
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176 · see citing works
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G. A., Malboeuf, C. M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,156 · see citing works
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works
Mutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100 · see citing works
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · see citing works
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074 · see citing works
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969 · see citing works
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 909 · see citing works
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831 · see citing works
Self-citation
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 796 · see citing works
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 794 · see citing works
Evidence for APOBEC3B mutagenesis in multiple human cancers
Burns, M. B., Temiz, N. A., & Harris, R. S. (2013) · Nature Genetics · doi:10.1038/ng.2701 · Cited by 763 · see citing works
The “cancer immunogram”
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748 · see citing works
A Compendium of Mutational Signatures of Environmental Agents
Kucab, J. E., Zou, X., Morganella, S., Joel, M., Nanda, A. S., Nagy, E., Gomez, C., Degasperi, A., Harris, R., Jackson, S. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.001 · Cited by 660 · see citing works
A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V., Hellmann, M., Solovyov, A., Rizvi, N., Merghoub, T., Levine, A., Chan, T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 624 · see citing works
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0237 · Cited by 623 · see citing works
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
Schrock, A. B., Ouyang, C., Sandhu, J. S., Sokol, E. S., Jin, D. X., Ross, J. S., Miller, V. A., Lim, D. W., Amanam, I. U., Chao, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz134 · Cited by 620 · see citing works
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 617 · see citing works
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieslik, M. P., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Yu, N., Wang, L., Kunju, L. P., Sarkar, N. D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 600 · see citing works
First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581 · see citing works
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579 · see citing works
Cancer Neoantigens
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 578 · see citing works
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M. M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 553 · see citing works
Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544 · see citing works
Biomarker: Predictive or Prognostic?
Ballman, K. V. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3651 · Cited by 520 · see citing works
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · see citing works
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Lauss, M., Donia, M., Harbst, K., Andersen, R. S., Mitra, S., Rosengren, F., Salim, M., Vallon‐Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 475 · see citing works
Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471 · see citing works
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Marty, R., Kaabinejadian, S., Rossell, D., Slifker, M. J., van de Haar, J., Engin, H. B., de Prisco, N., Ideker, T. E., Hildebrand, W. H., Font-Burgada, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.050 · Cited by 353 · see citing works
Implementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López‐Ríos, F., Merkelbach‐Bruse, S., Normanno, N., Rouleau, É., & Penault-Llorca, F. M. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 346 · see citing works
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Snyder, A., Nathanson, T., Funt, S. A., Ahuja, A., Buros, J. L., Hellmann, M. D., Chang, E., Aksoy, B. A., Al‐Ahmadie, H. A., Yusko, E. C., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002309 · Cited by 342 · see citing works
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322 · see citing works
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K. A., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 319 · see citing works
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 313 · see citing works
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 306 · see citing works
Self-citation
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Zinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J., Kuruvilla, J. G., Balakumaran, A., Zhang, Y., Chlosta, S., Shipp, M. A., & Armand, P. A. (2017) · Blood · doi:10.1182/blood-2016-12-758383 · Cited by 289 · see citing works
The Superior Efficacy of Anti-PD-1/PD-L1 Immunotherapy in KRAS-Mutant Non-Small Cell Lung Cancer that Correlates with an Inflammatory Phenotype and Increased Immunogenicity
Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281 · see citing works
Prevalence ofPDL1Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Goodman, A. M., Piccioni, D. E., Kato, S., Boichard, A., Wang, H., Frampton, G. M., Lippman, S. M., Connelly, C. F., Fabrizio, D. A., Miller, V. A., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 248 · see citing works
Self-citation
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma
Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233 · see citing works
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 232 · see citing works
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
Campesato, L. F., Barroso‐Sousa, R., Jimenez, L., Corrêa, B., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 224 · see citing works
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215 · see citing works
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Ericsson, P. I. G., Stovgaard, E. S., Sua, L. F., Reisenbichler, E., Kos, Z., Carter, J. M., Michiels, S., Quesne, J. P. C. L., Nielsen, T. O., Lænkholm, A., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5406 · Cited by 211 · see citing works
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Khagi, Y., Goodman, A. M., Daniels, G. A., Patel, S. P., Sacco, A. G., Randall, J. M., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1439 · Cited by 201 · see citing works
Self-citation
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Okamura, R., Kato, S., Lee, S., Jimenez, R. E., Sicklick, J. K., & Kurzrock, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000438 · Cited by 184 · see citing works
Self-citation
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
Tischkowitz, M. D., Huang, S., Banerjee, S. N., Hague, J., Hendricks, W. P. D., Huntsman, D. D., Lang, J. D., Orlando, K. A., Oza, A. M., Pautier, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3797 · Cited by 170 · see citing works
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Hogan, S. A., Courtier, A., Cheng, P. F., Jaberg-Bentele, N. F., Goldinger, S. M., Manuel, M., Perez, S., Plantier, N., Mouret, J.-F., Nguyen‐Kim, T. D. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0136 · Cited by 153 · see citing works
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 149 · see citing works
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
Kanjanapan, Y., Day, D., Wang, L., Al-Sawaihey, H., Abbas, E., Namini, A., Siu, L., Hansen, A., Razak, A., Spreafico, A., et al. (2019) · Cancer · doi:10.1002/cncr.31999 · Cited by 141 · see citing works
Adverse Events Associated with Immune Checkpoint Blockade
Tervaert, J.-W. C., Ye, C., & Yacyshyn, E. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1801663 · Cited by 134 · see citing works
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
Ikeda, S., Goodman, A. M., Cohen, P. R., Jensen, T. J., Ellison, C. K., Frampton, G. M., Miller, V. A., Patel, S. P., & Kurzrock, R. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.37 · Cited by 129 · see citing works
Self-citation
Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Galanina, N., Goodman, A. M., Cohen, P. R., Frampton, G. M., & Kurzrock, R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0121 · Cited by 125 · see citing works
Self-citation
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 123 · see citing works
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115 · see citing works
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H. A., Dietlein, F., He, M., Margolis, C. A., Elmarakeby, H., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 111 · see citing works
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Goodman, A. M., Castro, A., Pyke, R. M., Okamura, R., Kato, S., Riviere, P. J., Frampton, G. M., Sokol, E. S., Zhang, X., Ball, E. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00743-4 · Cited by 109 · see citing works
Self-citation
The emerging role of immune checkpoint inhibition in malignant lymphoma
Hude, I., Sasse, S., Engert, A., & Bröckelmann, P. J. (2016) · Haematologica · doi:10.3324/haematol.2016.150656 · Cited by 108 · see citing works
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
Marabelle, A., Fakih, M. G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz253.018 · Cited by 104 · see citing works
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Paz-Ares, L. G., Langer, C. J., Novello, S., Halmos, B., Cheng, Y., Gadgeel, S. M., Hui, R., Sugawara, S., Borghaei, H., Cristescu, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.078 · Cited by 104 · see citing works
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Aggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K., Hwang, W., Black, T. A., Yee, S. S., Christensen, T. E., Lariviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102 · see citing works
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Riviere, P. J., Goodman, A. M., Okamura, R., Barkauskas, D. A., Whitchurch, T. J., Lee, S., Khalid, N. K., Collier, R., Mareboina, M., Frampton, G. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0161 · Cited by 93 · see citing works
Self-citation
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
Wood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 89 · see citing works
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
Boichard, A., Pham, T. V., Yeerna, H., Goodman, A. M., Tamayo, P., Lippman, S. M., Frampton, G. M., Tsigelny, I. F., & Kurzrock, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1550341 · Cited by 88 · see citing works
Self-citation
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.142 · Cited by 88 · see citing works
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
Kowanetz, M., Zou, W., Shames, D. S., Cummings, C. A., Rizvi, N. A., Spira, A. I., Frampton, G. M., Lévêque, V., Flynn, S., Mocci, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.343 · Cited by 86 · see citing works
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
Budczies, J., Seidel, A., Christopoulos, P., Endris, V., Kloor, M., Győrffy, B., Seliger, B., Schirmacher, P., Stenzinger, A., & Denkert, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526613 · Cited by 80 · see citing works
Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
Peters, S., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A. V., Ahn, M., Baas, P., Cobo, M., Smolin, A., Vicente, D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct074 · Cited by 78 · see citing works
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
Boichard, A., Tsigelny, I. F., & Kurzrock, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284719 · Cited by 75 · see citing works
Self-citation
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma
Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J., & Chuang, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39594-4 · Cited by 74 · see citing works
Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)
Singavi, A. K., Menon, S., Kilari, D., Alqwasmi, A., Ritch, P. S., Thomas, J. P., Martin, A. L., Oxencis, C. J., Ali, S. S., & George, B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.006 · Cited by 73 · see citing works
Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy
Hosoi, A., Takeda, K., Nagaoka, K., Iino, T., Matsushita, H., Ueha, S., Aoki, S., Matsushima, K., Kubo, M., Morikawa, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19548-y · Cited by 69 · see citing works
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 66 · see citing works
Self-citation
Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
Chen, X., Su, C., Ren, S., Zhou, C., & Jiang, T. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.52 · Cited by 65 · see citing works
TCR repertoires of intratumoral T‐cell subsets
Linnemann, C., Mezzadra, R., & Schumacher, T. N. (2013) · Immunological Reviews · doi:10.1111/imr.12140 · Cited by 63 · see citing works
Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy
Wang, C., Gong, J., Tu, T. Y., Lee, P. P., & Fakih, M. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.09 · Cited by 62 · see citing works
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Kim, E. S., Velcheti, V., Mekhail, T. M., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., Hu, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.067 · Cited by 62 · see citing works
The Peptide-Receptive Transition State of MHC Class I Molecules: Insight from Structure and Molecular Dynamics
Mage, M. G., Dolan, M. A., Wang, R. Y., Boyd, L. F., Revilleza, M. J., Robinson, H. H., Natarajan, K., Myers, N. B., Hansen, T. H., & Margulies, D. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200831 · Cited by 59 · see citing works
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma
Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 59 · see citing works
Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
Pham, T. V., Boichard, A., Goodman, A. M., Riviere, P. J., Yeerna, H., Tamayo, P., & Kurzrock, R. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12748 · Cited by 57 · see citing works
Self-citation
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
Müller, J. N., Falk, M., Talwar, J., Neemann, N., Mariotti, E., Bertrand, M., Zacherle, T., Lakis, S., Menon, R., Gloeckner, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.014 · Cited by 56 · see citing works
Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study
Galsky, M. D., Saci, A., Szabó, P. M., Azrilevich, A., Horak, C. E., Lambert, A., Siefker-Radtke, A. O., Necchi, A., & Sharma, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx371.003 · Cited by 56 · see citing works
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Socinski, M. A., Velcheti, V., Mekhail, T. M., Chae, Y. K., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.081 · Cited by 56 · see citing works
Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Jardim, D. L. F., Gagliato, D. D. M., Giles, F. J., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1970 · Cited by 54 · see citing works
Self-citation
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Galanina, N., Bejar, R. L., Choi, M. Y., Goodman, A. M., Wieduwilt, M. J., Mulroney, C. M., Kim, L., Yeerna, H., Tamayo, P., Vergilio, J., et al. (2018) · Cancers · doi:10.3390/cancers11010011 · Cited by 53 · see citing works
Self-citation
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Meiri, E., Garrett-Mayer, E. S., Halabi, S., Mangat, P. K., Shrestha, S., Ahn, E. R., Osayameh, O., Perla, V., & Schilsky, R. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.133 · Cited by 52 · see citing works
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Pyke, R. M., Thompson, W. K., Salem, R. M., Font-Burgada, J., Zanetti, M., & Carter, H. K. (2018) · Cell · doi:10.1016/j.cell.2018.11.050 · Cited by 45 · see citing works
Evolutionary pressure against MHC class II binding cancer mutations
Pyke, R., Thompson, W., Salem, R., Font-Burgada, J., Zanetti, M., & Carter, H. (2018) · Cell · doi:10.1016/j.cell.2018.08.048 · Cited by 44 · see citing works
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Powles, T. B., Loriot, Y., Ravaud, A., Vogelzang, N. J., Durán, I., Retz, M. M., Giorgi, U. D., Oudard, S. M., Bamias, A., Koeppen, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.409 · Cited by 43 · see citing works
Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma
Siefker-Radtke, A. O., Apolo, A. B., Bivalacqua, T. J., Spiess, P. E., & Black, P. C. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.10.041 · Cited by 38 · see citing works
Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Seiwert, T. Y., Haddad, R. I., Bauml, J. M., Weiss, J., Pfister, D. G., Gupta, S., Mehra, R., Gluck, I., Kang, H., Worden, F. P., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-lb-339 · Cited by 38 · see citing works
Biomarkers predictive of response to pembrolizumab in head and neck cancer
Pfister, D., Haddad, R., Worden, F., Weiss, J., Mehra, R., Chow, L. Q. M., Liu, S. V., Kang, H., Saba, N., Wirth, L., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5434 · Cited by 38 · see citing works
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
Goodman, A. M., Kato, S., Chattopadhyay, R., Okamura, R., Saunders, I. M., Montesion, M., Frampton, G. M., Miller, V. A., Daniels, G. A., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0716 · Cited by 35 · see citing works
Self-citation
Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA).
Davis, A. A., Chae, Y. K., Agte, S., Pan, A. P., Simon, N. I., Taxter, T., Behdad, A., Carneiro, B. A., Cristofanilli, M., & Giles, F. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e23028 · Cited by 28 · see citing works
Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.
Cristescu, R., Mogg, R., Ayers, M., Albright, A. V., Murphy, E., Yearley, J. H., Sher, X., Liu, X., Nebozhyn, M., Lunceford, J. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.7_suppl.1 · Cited by 15 · see citing works
Correlation between tumor mutation burden and response to immunotherapy.
Bonta, I. R., Isac, J. F., Meiri, E., Bonta, D., & Rich, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e14579 · Cited by 14 · see citing works
Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
Barroso‐Sousa, R., Jain, E., Kim, D., Partridge, A. H., Cohen, O., & Wagle, N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1010 · Cited by 14 · see citing works
Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab
Weber, J. S., Horak, C. E., Hodi, F. S., Chang, H., Woods, D. M., Sanders, C. M., Robins, H. S., & Yusko, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw378.01 · Cited by 13 · see citing works
Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database
Singal, G., Miller, P. G., Agarwala, V., Li, G., Gossai, A., Albacker, L. A., Goldberg, M. E., He, J., Frank, S., Bourque, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.005 · Cited by 12 · see citing works
T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).
Reuben, A., Zhang, J. J., Lin, H. Y., Little, L., Gumbs, C. E., Tran, H. T., Wang, L., Haymaker, C., Mehran, R. J., Rice, D. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8532 · Cited by 5 · see citing works
Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.
Fakih, M., Sandhu, J. S., Ouyang, C., Sokol, E. S., Ross, J. S., Miller, V. A., Lim, D. W., Chao, J., Catenacci, D. V. T., Cho, M. T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.43 · Cited by 5 · see citing works
Financial toxicity, financial well-being, and quality of life among bladder cancer patients.
Tucker‐Seeley, R. D., Tang, W., Steinberg, L., Banks, S., Bolton, H., & Bhanvadia, S. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.29_suppl.133 · Cited by 4 · see citing works
Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma.
Lee, C., Natale, R. G. D., Chowell, D., Makarov, V., Redzematovic, A., Murray, S. J., Carlo, M. I., Voss, M. H., Feldman, D. R., Motzer, R. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.641 · Cited by 1 · see citing works

Flagged first, then by citations

2 of the 151 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Galsky MD, Saci A, Szabo PM, Azrilevich A, Horak C, Lambert A, Siefker-Radtke A, Necchi A, and Sharma P (2017b). Impact of tumormutation burden on nivolumab efficacy in secondline urothelial carcinoma patients: exploratory analysis of the phase II checkmate 275 study. Annals of Oncology 28, v295– v329.

Sorted by citations

Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 747 · see citing works
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598 · see citing works
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468 · see citing works
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391 · see citing works
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
Palmeri, M., Mehnert, J. M., Silk, A. W., Jabbour, S. K., Ganesan, S., Popli, P., Riedlinger, G., Stephenson, R. D., de Meritens, A. B., Leiser, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100336 · Cited by 355 · see citing works
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359 · see citing works
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. Q. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 284 · see citing works
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
Zhang, M., Liu, C.-J., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 296 · see citing works
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
So, J. Y., Ohm, J. E., Lipkowitz, S., & Li, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108253 · Cited by 262 · see citing works
The coming decade in precision oncology: six riddles
Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiß, A., Lichter, P., & Kurzrock, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00529-3 · Cited by 214 · see citing works
Self-citation
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jérusalem, G., Hubert, P., & Herfs, M. F. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 213 · see citing works
SMARCA4 : Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
Mardinian, K., Adashek, J. J., Botta, G. P., Kato, S., & Kurzrock, R. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0433 · Cited by 197 · see citing works
Self-citation
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Cui, J., Li, Y., Yang, Y., Yang, H., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J., Wang, R. L., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 202 · see citing works
Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges
Chavda, V. P., Patel, A., Mistry, K. J., Suthar, S. F., Wu, Z., Chen, Z., & Hou, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867655 · Cited by 190 · see citing works
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Kim, E. S., Velcheti, V., Mekhail, T. M., Yun, C., Shagan, S. M., Hu, S., Chae, Y. K., Leal, T. A. B., Dowell, J. E., Tsai, M. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01754-x · Cited by 181 · see citing works
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 172 · see citing works
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui, M., Cooper, T. J., Kalkar, P., Schif‐Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Rottem, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 168 · see citing works
Predictive biomarkers of colon cancer immunotherapy: Present and future
Hou, W., Cheng, Y., & Zhu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032314 · Cited by 147 · see citing works
T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing
Chi, H., Zhao, S., Yang, J., Gao, X., Peng, G., Zhang, J., Xie, X., Song, G., Xu, K., Xia, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1137025 · Cited by 149 · see citing works
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145 · see citing works
Impact of risk factors on early cancer evolution
Weeden, C. E., Hill, W., Lim, E. L., Gronroos, E. C., & Swanton, C. (2023) · Cell · doi:10.1016/j.cell.2023.03.013 · Cited by 143 · see citing works
Photodynamic therapy combined with immunotherapy: Recent advances and future research directions
Warszyńska, M., Repetowski, P., & Dąbrowski, J. M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215350 · Cited by 138 · see citing works
Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study
Guo, S., Hu, L.-S., Huang, W.-J., Zhou, Z.-Z., Luo, H., & Tian, X. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001479 · Cited by 139 · see citing works
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
de Rodas, M. L., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M. A., Corredor, G., Barrera, C., Behlman, L., Rimm, D. L., Herbst, R. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004440 · Cited by 130 · see citing works
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 134 · see citing works
Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma
Wang, F., Lin, H., Su, Q., & Li, C. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02727-7 · Cited by 116 · see citing works
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 118 · see citing works
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 113 · see citing works
Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Li, M., Wang, L., Cong, L., Wong, C. C., Zhang, X., Chen, H., Zeng, T., Li, B., Jia, X., Huo, J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000591 · Cited by 107 · see citing works
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis
Deng, H., Zhao, Y., Cai, X., Chen, H., Cheng, B., Zhong, R., Li, F., Xiong, S., Li, J., Liu, J., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103582 · Cited by 103 · see citing works
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 102 · see citing works
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects
Hou, W., Zhao, Y., & Zhu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015321 · Cited by 88 · see citing works
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 88 · see citing works
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 83 · see citing works
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 89 · see citing works
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
Wang, J., Xiu, J., Farrell, A. P., Baca, Y., Arai, H., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00783-5 · Cited by 82 · see citing works
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 84 · see citing works
The evolving landscape of tissue‐agnostic therapies in precision oncology
Subbiah, V., Gouda, M. A., Ryll, B., Burris, H. A., & Kurzrock, R. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21844 · Cited by 85 · see citing works
Self-citation
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors
Zapata, L., Caravagna, G., Williams, M. J., Lakatos, E., AbdulJabbar, K., Werner, B., Chowell, D., James, C. T., Gourmet, L. E., Milite, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01313-1 · Cited by 76 · see citing works
Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
Lenis, A. T., Ravichandran, V., Brown, S., Alam, S. M., Katims, A., Truong, H., Reisz, P. A., Vasselman, S., Nweji, B., Autio, K. A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3403 · Cited by 79 · see citing works
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Tateo, V., Marchese, P. V., Mollica, V., Massari, F., Kurzrock, R., & Adashek, J. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040614 · Cited by 72 · see citing works
Self-citation
Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma
Wang, X., Liu, C., Chen, J., Chen, L., Ren, X., Hou, M., Cui, X., Jiang, Y., Liu, E., Zong, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00445-8 · Cited by 68 · see citing works
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 67 · see citing works
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 73 · see citing works
ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
Zhu, G., Shi, R., Li, Y., Zhang, Z., Xu, S., Chen, C., Cao, P., Zhang, H., Liu, M., Pan, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670040 · Cited by 67 · see citing works
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer
Ding, S., Qiao, N., Zhu, Q., Tong, Y., Wang, S., Chen, X., Tian, Q., Xiao, Y., & Shen, K. (2023) · 癌症：英文版 · doi:10.1002/cac2.12429 · Cited by 68 · see citing works
Advancing precision oncology with AI-powered genomic analysis
Srivastava, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591696 · Cited by 72 · see citing works
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 66 · see citing works
Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients
Chi, H., Peng, G., Wang, R., Yang, F., Xie, X., Zhang, J., Xu, K., Gu, T., Yang, X., & Tian, G. (2022) · Cells · doi:10.3390/cells11213436 · Cited by 66 · see citing works
OX40/OX40 ligand and its role in precision immune oncology
Thapa, B., Kato, S., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M., Previs, R. A., Conroy, J., DePietro, P., Pabla, S., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10184-9 · Cited by 66 · see citing works
Self-citation
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
Gantzer, J., Davidson, G., Vokshi, B., Weingertner, N., Bougoüin, A., Moreira, M., Lindner, V., Lacroix, G., Mascaux, C., Chenard, M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac040 · Cited by 65 · see citing works
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy
Chen, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102606 · Cited by 65 · see citing works
Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?
Wang, C., Zhang, L., Vakiani, E., & Shia, J. (2022) · Modern Pathology · doi:10.1038/s41379-022-01109-4 · Cited by 63 · see citing works
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 69 · see citing works
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
Klein, O., Kee, D., Markman, B., Carlino, M. S., Underhill, C. R., Palmer, J., Power, D., Cebon, J. S., & Behren, A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.005 · Cited by 61 · see citing works
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 61 · see citing works
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Segura‐Collar, B., Hiller-Vallina, S., de Dios, O., Caamaño-Moreno, M., Mondéjar-Ruescas, L., Sepúlveda-Sánchez, J. M., & Gargini, R. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01569-y · Cited by 61 · see citing works
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer
Wang, J., Qin, D., Tao, Z., Wang, B., Xie, Y., Wang, Y., Li, B., Cao, J., Qiao, X., Zhong, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1056932 · Cited by 57 · see citing works
Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging
Monkman, J. H., Moradi, A., Yunis, J., Ivison, G. T., Mayer, A. T., Ladwa, R., O'Byrne, K. J., & Kulasinghe, A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05035-8 · Cited by 57 · see citing works
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Li, S., Wu, X., Yan, X., Zhou, L., Chi, Z., Si, L., Cui, C., Tang, B., Mao, L., Lian, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004036 · Cited by 56 · see citing works
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Peng, Z., Li, M., Li, H., & Gao, Q. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103666 · Cited by 56 · see citing works
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
Zhang, G., Yuan, J., Pan, C., Xu, Q., Cui, X., Zhang, J., Liu, M., Song, Z., Wu, L., Wu, D., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104515 · Cited by 56 · see citing works
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Federico, A. D., Alden, S. L., Smithy, J. W., Ricciuti, B., Alessi, J. V., Wang, X., Pecci, F., Lamberti, G., Gandhi, M. M., Vaz, V. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.014 · Cited by 55 · see citing works
Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy
Liu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113618 · Cited by 54 · see citing works
Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma
Gabbia, D., & Martin, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043441 · Cited by 54 · see citing works
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 61 · see citing works
A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer
Wang, H., Liu, J., Jiang, Y., Wang, Z., Zhang, Z., Peng, J., Wang, Y., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943389 · Cited by 53 · see citing works
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
Xu, S., Zheng, Y., Ye, M., Shen, T., Zhang, D., Li, Z., & Lu, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-12843-0 · Cited by 53 · see citing works
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 52 · see citing works
CAR T cell therapies for diffuse midline glioma
Thomas, B. C., Staudt, D. E., Douglas, A. M., Monje, M., Vitanza, N. A., & Dun, M. D. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.007 · Cited by 50 · see citing works
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 50 · see citing works
Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
Menon, V., & Brash, D. E. (2023) · Mutation Research - Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108471 · Cited by 48 · see citing works
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 48 · see citing works
Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
Chang, L.-C., Liu, J., Zhu, J.-L., Guo, S., Wang, Y., Zhou, Z., & Wei, X. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0376 · Cited by 72 · see citing works
Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection
Wehrle, C. J., Hong, H., Kamath, S. D., Schlegel, A. A., Fujiki, M., Hashimoto, K., Kwon, C. H. D., Miller, C. C., Walsh, R. M., & Aucejo, F. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006386 · Cited by 47 · see citing works
Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 49 · see citing works
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 50 · see citing works
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Murray, J. C., Sivapalan, L., Hummelink, K., Balan, A., White, J. R., Niknafs, N., Rhymee, L., Pereira, G., Rao, N., Weksler, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1469 · Cited by 45 · see citing works
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024) · Genes · doi:10.3390/genes15040468 · Cited by 48 · see citing works
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 49 · see citing works
Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 47 · see citing works
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46 · see citing works
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41 · see citing works
Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Park, J. C., Krishnakumar, H. N., & Saladi, S. V. (2022) · Current Oncology · doi:10.3390/curroncol29060334 · Cited by 42 · see citing works
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 43 · see citing works
Engineering a Multifunctional Nanozyme Platform for Synergistic Melanoma Therapy: Integrating Enzyme Activity, Immune Activation, and Low‐Temperature Photothermal Effects
Ding, Q., Liu, H., Yan, L., Chen, L., Chen, Y., Kim, J. S., & Mei, L. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505911 · Cited by 42 · see citing works
Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types
Shi, Z., Chen, B., Han, X., Gu, W., Liang, S., & Wu, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-35092-w · Cited by 41 · see citing works
Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer
Seclì, L., Leoni, G., Ruzza, V., Siani, L., Cotugno, G., Scarselli, E., & D’Alise, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316591 · Cited by 41 · see citing works
Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy
Bao, X., Lin, X., Xie, M., Yao, J., Song, J., Ma, X., Zhang, X., Zhang, Y., Liu, Y., Han, W., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413067 · Cited by 42 · see citing works
Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy
Jensen, C., Nissen, N. I., von Arenstorff, C. S., Karsdal, M. A., & Willumsen, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02133-z · Cited by 40 · see citing works
Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
Bafaloukos, D. I., Gazouli, I., Koutserimpas, C., & Samonis, G. (2023) · Vaccines · doi:10.3390/vaccines11030636 · Cited by 41 · see citing works
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
Baas, I. O., Westermann, A. M., You, B., Bolze, P., Seckl, M. J., & Ghorani, E. (2023) · Gynecologic and Obstetric Investigation · doi:10.1159/000533972 · Cited by 38 · see citing works
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy
Bao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 39 · see citing works
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges
Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 37 · see citing works
Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients
Jiang, Q., Sun, J., Chen, H., Ding, C., Tang, Z., Ruan, Y., Liu, F., & Sun, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650673 · Cited by 36 · see citing works
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41 · see citing works
“The clinical utility of other biomarkerssuchastheTumorMutationalBurden(TMB)hasbeenexplored inseveraldifferentclinicaltrials 11 – 14 .”
Biomarker discovery and application—An opportunity to resolve the challenge of liver cancer diagnosis and treatment
Chen, J., Niu, C., Yang, N., Liu, C., Zou, S., & Zhu, S. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106674 · Cited by 35 · see citing works
Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 36 · see citing works
Interplay of Sphingolipid Metabolism in Predicting Prognosis of GBM Patients: Towards Precision Immunotherapy
Wang, Q., Zheng, C., Hou, H., Bao, X., Tai, H., Huang, X., Li, Z., Li, Z., Wang, Q., Pan, Q., et al. (2023) · Journal of Cancer · doi:10.7150/jca.89338 · Cited by 35 · see citing works
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
Yu, G., Pang, Y. K., Merchant, M., Kesserwan, C. A., Gangalapudi, V., Abdelmaksoud, A. A., Ranjan, A., Kim, O., Wei, J. S., Chou, H.-C., et al. (2021) · Cancers · doi:10.3390/cancers13236092 · Cited by 35 · see citing works

The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine
Elbehi, M. A. (2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.6 · Cited by 3 · see citing works
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 48 · see citing works
Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
Lee, M., Samstein, R., Valero, C., Chan, T., & Morris, L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1631136 · Cited by 61 · see citing works
TMB or not TMB as a biomarker: That is the question
Addeo, A., Friedlaender, A., Banna, G. L., & Weiss, G. J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103374 · Cited by 220 · see citing works
The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
Nandakumar, V., & Mills, J. R. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.295097 · Cited by 13 · see citing works

Authors: Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R.
Affiliations: Hospital Sírio-Libanês (BR)
University of California San Diego (US)
Corresponding author: Kurzrock, Razelle
ORCID: Jardim, Denis L.
Goodman, Aaron
Kurzrock, Razelle
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2021-02
Volume: 39
Issue: 2
Pages: 154-173
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.10.001
PMC: PMC7878292
OpenAlex: W3097803258
Cited by: 1,192
References: 151
Citations by year: 2026: 134 · 2025: 263 · 2024: 294 · 2023: 276 · 2022: 171 · 2021: 53 · 2020: 1
FWCI: 13.60
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 372 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Astellas Pharma US
National Cancer Institute (P30 CA023100)
Janssen Pharmaceuticals
AstraZeneca
Bristol-Myers Squibb
Genentech
Roche
EMD Serono
Pfizer
Meso Scale Diagnostics
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: tumor mutational burden, immunotherapy biomarkers, immune checkpoint inhibitors, neoantigens, MHC class I antigen presentation, T cell receptor repertoire, cancer immunotherapy response prediction
MeSH terms: Immune Checkpoint Inhibitors, Humans, Immunotherapy, Major Histocompatibility Complex, Mutation, Neoplasms, T-Lymphocytes, Biomarkers, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks